Peter Martin, Chief Operating Officer, Norgine said: “Norgine is very pleased that the true value of TARGAXAN 550 has been recognised. It is a reflection of the value this medicine brings to patients, carers and the healthcare system, as demonstrated in the real world data that was submitted. It is critical to have additional treatment options for hepatic encephalopathy as liver disease is increasing and there is currently no cure for HE apart from liver transplantation.”
Richard Hall, co-founder, Liver4Life, said: “As someone with personal experience of caring for a close relative with this devastating condition, I am delighted with NICE’s decision to approve this vitally important treatment.Treatment options are extremely limited for patients with HE with no other new options being made available since lactulose was launched in 1969.Clinicians are now able to offer a treatment that actually makes a tremendous difference to the quality of life for patients and their families.”
Andrew Langford, chief executive, British Liver Trust, said: “In my opinion, rifaximin offers an invaluable treatment for people with HE and significantly improves both their and their carers quality of life. As a charity that works with many people affected by HE, the British Liver Trust is very pleased with NICE’s decision.”
Norgine currently holds marketing rights for XIFAXAN 550mg (known as TARGAXAN in the UK and some other markets) in Australia, Belgium, Denmark, Finland, France, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden, United Kingdom and Switzerland. The product is reimbursed in Scotland, Ireland, Australia, Germany and Luxembourg.
1. NICE, Final Appraisal Determination, ‘Rifaximin for preventing episodes of overt hepatic encephalopathy’, published 19 February 2014 and available online at www.nice.org.uk
2. Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol. 1986;3(1):75-82.
3. Gilberstadt SJ, Gilberstadt H, Zieve L, Buegel B, Collier RO, Jr., McClain CJ. Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Arch Intern Med. Apr 1980;140(4):519-521
4. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. May 2001;16(5):531-535.
5. TARGAXAN® 550 Summary of Product Characteristics, www.medicines.org.uk/emc/medicine/27427/SPC/TARGAXAN+550+mg+film-coated+tablets/